More News26 Nov 2019 | 2:49 PM

Thiruvananthapuram, Nov 26 (UNI) National Institute of Speech and Hearing (NISH) has celebrated the 70th Constitution Day at its campus in Akkulam on Tuesday.

Sabarimala, Nov 26 (UNI) As many as 8 Ayyappa devotees were injured, two of them seriously, when a huge tree fell on them while they were trekking on the Chandranandan road near Marakkuttam, here in the wee hours on Tuesday.

Mangaluru, Nov 26 (UNI) ACP Squad in an operation arrested an Indian Army imposter Manjunath Reddy who was posing himself as Indian Army Junior Commissioned officer, at a his residence in Suratkal.

Mysuru, Nov 26 (UNI) Karnataka Chief Minister BS Yediyurappa on Tuesday expressed confident that BJP would sweep the upcoming 15 Assembly seats and that would put an end to all talks around mid-term polls in the state.

Udupi, Nov 26 (UNI) District Administration and police have warned devotees and tourists about fake website created by miscreants in the name of Sri Mookambika Temple at Kollur.

Originally posted here:
Jipmer conducts JIPP 2019 - United News of India

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Companys ThyGeNEXT test, representing an increase of approximately $2,400 per assay over previous reimbursement coverage. This increase in reimbursement rates reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery. In 2018, Interpace processed approximately 12,500 ThyGeNEXT tests.

Prior to the new LCD code (81455) becoming effective, it was subject to a public comment period, which ended December 15, 2019, and is now subject to an analysis and review period by MACs Medical Directors. Final approval is expected during the first quarter of 2020. ThyGeNEXT has been covered by an existing LCD since it was launched in mid-2018 and its predecessor, ThyGenX, has been covered since 2014.

Jack Stover, President & CEO of Interpace, said, I am very pleased with the draft local coverage announcement and look forward to the final determination, which when approved will demonstrate the quality of our expanded assay, and most importantly supports continued reimbursement for patients and their families potentially affected by Thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace Biopharma provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Story continues

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

See more here:
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT - Yahoo Finance

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Bioinformatics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The scope of the study encompasses the global bioinformatics market based on geography, category, and application. It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market.

It discusses the ways in which bioinformatics has been utilized by the pharma and biotech industries to streamline the research and development (R&D) process and improve efficiencies. It provides a detailed analysis of the leading countries, companies, and technologies that will drive the field forward.

The report includes:

The rapid growth in raw data generation and advances in IT software and infrastructure have enabled researchers to integrate disparate datasets in order to decipher complex biological processes and develop predictive models of disease, for the purposes of identifying and validating novel biomarkers and developing precision medicines.

Since scientists unraveled the blueprint of the human genome more than 10 years ago, they have been exploring new ways to utilize omic data to understand more complex diseases. Researchers are eager to analyze as many different types of data as possible to gain a better understanding of what is happening at the cellular and molecular levels. Service providers have developed new analytical tools and IT infrastructures to enable scientists to interrogate complex data sources and quickly and efficiently disseminate information for better decision-making to achieve this goal.

More recently, improvements in cloud computing capabilities, advances in data analysis software services and the growth of NGS technologies have helped to expand the evaluation of available datasets, allowing researchers to build systems biology models of various diseases.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Global Bioinformatics Market: Overview

Chapter 4 Bioinformatics: Data Generation and Data Management

Chapter 5 Bioinformatics: Data Analysis and Software

Chapter 6 Bioinformatics: Data Processing and Storage

Chapter 7 Bioinformatics: Sequencing Services and Platforms

Chapter 8 Bioinformatics: Sequencing Applications

Chapter 9 Bioinformatics Applications in Pharmaceutical R&D

Chapter 10 Market Trends and Analysis

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ywqdiu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the article here:
Analysis on the World's Bioinformatics Market 2017-2019 and Forecast to 2023 - Review of Challenges & Opportunities following the Adoption of...

Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.

For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that a full third of DCM patients inherit the condition from their parents or other family members. Germline testing can identify patients with this genetic variant, leading clinicians to a faster diagnosis and earlier treatment. The Food and Drug Administration (FDA) has stated its commitment to approving targeted therapies based on genetic mutations as appropriate. Payers are beginning to issue reimbursement policies to cover the cost of genetic/genomic testing. United Healthcare, for instance, began covering pharmacogenomic panels for patients with anxiety and depression this October.

This leads us to the next great transformation necessitated by precision medicine: implementing the technology infrastructure to govern the ordering and resulting processes inherent to genomics, as well as finding ways to manage the great volumes of data generated by testing.

Precision medicine is already being pursued sporadically across many, if not most, healthcare organizations. Oncologists are likely to be ordering somatic tests to better profile patient tumors so targeted therapies can be delivered. Family practice, behavioral medicine and psychiatric departments are using pharmacogenomics to understand how well (or poorly) patients metabolize specific medications and which might trigger side effects or safety concerns. These insights allow them to prescribe the right treatment at the right dose the first time around instead of spending months on a trial-and-error approach.

Cardiovascular and neurology specialists (among others) order germline tests to help them diagnose, treat and gain new insights into many common conditions such as congestive heart failure, arrhythmias, aneurysms, epilepsy, nerve pain and dementia. Some health systems even order germline tests on all newborns so a full genetic profile is available which can be used throughout the individuals lifetime.

The value of the data being generated through these clinical pockets cannot be understated. It carries information that can be used across a multitude of care settings far into the future to help providers and specialists arrive at more accurate diagnoses faster, and identify the most effective treatment sooner. This, in turn, can help healthcare leaders move the needle to improve quality efforts and optimize revenue while reducing the risk associated with poor outcomes.

To realize full value, however, healthcare organizations must ensure genetic/genomic test results are readily available to clinicians at the point of care and in a vocabulary that makes them meaningful. Unfortunately, few health systems have invested in the IT resources that can make this possible. Currently, test results are ordered in a vacuum and results are often returned in a PDF that will be hard to access. In addition, the information is relayed in a nomenclature unfamiliar to clinicians, so they struggle to understand how to apply the results to specific patient circumstances.

Unless these concerns are addressed, healthcare will simply reenact a mistake made years ago with the advent of electronic health records: valuable data that can immediately and directly impact care will be locked in a silo, unavailable during clinical decision-making.

As the industry heads into 2020, it must make plans and take action to get ahead of this looming problem. Healthcare IT professionals must be brought to the table to help organizations strategize about their precision medicine initiatives. The key to success with this new standard of care is recognition that data generated by genetic/genomic tests can be used endlessly across the enterprise and over the long term as patient conditions change. Organizations must seek out platforms that will consume genomic test results as discrete data and integrate it with patient-specific clinical information. Likewise, the platforms must be made available within existing workflows, so clinicians can leverage it during decision making and can interrogate the data as patient conditions change and genomic science delivers new insights.

Picture: Feodora Chiosea, Getty Images

Read the original:
IT will be key to precision medicine's success in 2020 - MedCity News

Clover Health similar to many other Medicare Advantage (MA) players has its sights firmly set on the home.

But unlike its larger and older MA peers, the relatively smaller and newer Clover isnt held back by certain structural constraints. That ability to build a home-focused model from the ground up is a big part of Clovers future, Chief Scientific Officer Kumar Dharmarajan told Home Health Care News.

And the technology-enabled Clovers future is bright: Founded in 2013, San Francisco-based Clover has raised about $925 million since launching. Among its backers: Google parent company Alphabet Inc. (Nasdaq: GOOGL).

HHCN recently caught up with Clovers Dharmarajan to learn all about its in-home care ambitions, its approach to partnerships and evolution into a payer-provider hybrid.

Highlights from that conversation are below, edited for length and clarity.

Dharmarajan: If youre asking about specific bids and plan offerings, those vary by location. Clover doesnt just have one U.S. plan, in other words.

We have a number of different offerings where we engage with members in the home. One of those is our in-home care program, where we provide in-home primary care services for some of our most vulnerable members, people with multiple chronic conditions, frailty and advanced illness.

Many of these folks are frequently hospitalized and have limited life expectancies. For those members, we wanted to provide a technology-enabled house calls experience. House calls have been shown by CMS and some of its demos to be really important to those who have trouble accessing care, including those who are homebound.

Advertisement

Many of the Clover members in this program do have difficulty leaving the home.

We give them access to physicians, nurses, social workers people who will see them monthly if needed. Theyll spend an hour or so at a time with our members. Contrast that to getting 10 minutes with your doctor in the office.

We focus on very comprehensive, holistic care thats aligned with members values, preferences and prognosis. We provide a number of interventions that are on the cutting-edge side.

We do pharmacogenomics testings. We want to make sure members medication regimens are best-aligned with how their bodies metabolize drugs. A lot of folks are on 10, 15 medications.

In some of these cases, its like a witchs brew, right? We want to make sure the regimen our members are on promotes their health and doesnt cause side effects.

For some of our members, we also give them access to what we call the Clover button, which is an ability for them to contact their provider directly. They dont have to remember a phone number. They just press a button, then they could talk through that and speak with their medical team.

And we do a bunch of other things where we really integrate payer and provider. Clover is a technology-enabled health insurance company, but this in-home care practice, this house calls practice is wholly owned by Clover.

Clover the health plan has access to a lot of different streams of medical information that we provide to Clover the practice.

For example, we often know when a member of ours is hospitalized or heads to the ER. We can get real-time data feeds a lot of times from those institutions. We then feed that info to the medical practice so they know exactly when a person leaves. In turn, we can engage with those individuals in the home as soon as theyre discharged.

Were really excited about that partnership between plan and provider.

At this point, Clover does not provide skilled home health services and things that fall into that bucket. We do have social workers who see our members and help with financial challenges. We have nurses who are part of our team, experts who are well-trained in, for example, wound management.

Were not trying to be a home health agency, but we do have some of those skillsets naturally within the team. And we do partner with home health agencies to really advance the care of our members.

In general, home health is probably underutilized for a lot of frail elders. We look to use home health care wherever it could benefit a member.

Unfortunately, its not a coincidence that some of the sickest, most vulnerable patients are also the most vulnerable from a social perspective, whether thats in regard to finances, housing, food or language barriers. For us, addressing social determinants is just part and parcel of the practice.

Its not something that we see as a unique strategy or something new that we need to suddenly start doing.

Its certainly en vogue now to talk about addressing social determinants of health. We just think its always been very core to the model of, you know, improving care for homebound older adults.

Regardless of that, committing to a home-based strategy is something that Clover has been interested in doing and has been investing in for some time. Home-based care is very scalable compared to brick and mortar.

Its also clear to us that home-based care allows you to pick up on and address issues that you would never see in an office setting. You go into the home of an older adult, you see six different bottles of insulin, all of which are different. This literally just happened with one of our members, who was actually blind. She didnt know which [insulin] to take.

When you go into the home, you see that. You can see whats in the refrigerator. You can engage with family members. Theres an incredible amount of data.

With our in-home care program, weve seen reductions in [hospital] admission rates, reductions in ER visitation rates. Weve seen reduced medical expenses overall. And weve heard from a lot of members who are just positive and grateful for the program.

Many people have never had house calls before.

I dont think I can tell you our specific partners at this point. But generally, I think there are a few things that are very important to us.

One is responsiveness. If you have a home health need, being able to quickly make the referral and have a team get in there ASAP is so critical.

Also having bi-directional communication is important. Once the home health provider is in there working with our member, we want to hear from that provider if they see something theyre concerned with. Even if its just, The member doesnt look at good today.

Provider groups need to be collaborators and, in a sense, sensors. Home health providers might be in the home more frequently than we are, depending on a members needs.

We have spoken with some and have embarked on some pilots. We do recognize that non-skilled services are an important part of the overall picture.

Read more:
Alphabet-Backed Insurer Clover Health Committing to Home-Based Strategy - Home Health Care News

PGRN-Hub will encourage and support participation of all investigators with an interest in precision medicine through establishment of an efficient and innovative infrastructure that promotes scientific exchange through the following aims:

Aim 1.Provide support and infrastructure for PGRN meetings, conference calls and webinars that use information technologies and novel meeting activities to enhance communication and scientific exchange. In particular, we will provide logistical and technical support for (a) at least two PGRN annual meetings at designated PGRN sites and (b) regular conference calls and webinars.

Aim 2.Establish a PGRN Virtual Home to enhance and promote communications among PGRN members and with scientific and public audiences while attracting new membership. In particular, we will (a) develop and promote a web interface to unify, organize, and display all PGRN resources and activities at pgrn.org; (b) host lectures and display professional-quality presentations that highlight up-to-date PGRN accomplishments; and (c) establish an intranet to handle PGRN meeting logistics and to support PGRN webinars and internal collaborations.

Aim 3.Promote a collaborative and synergistic network by (a) incorporating networking opportunities into our meetings; (b) soliciting open proposals to develop and incubate new ideas for collaborations; and (c) providing access to information from key resources that will support the conduct of the proposed collaborative projects including PGRN Enabling Resources such as RPGEH.

Read the original post:
PGRN Hub - PGRN Hub

Interpace hosts 2nd Annual Fellow Programs

PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid and GI products at an industry known scientific international meeting. The American College of Gastroenterology annual meeting is held on October 27-30 in San Antonio, Texas and is one of the largest gatherings of gastroenterologists and endoscopists. These are two key targets for Interpaces PancraGEN test for early detection of cancer in indeterminate pancreatic cysts, solid lesions, and biliary structures. The PancraGEN publication entitled Serial molecular testing of pancreatic cyst fluid over time: progression and regression highlights the Companys unique clinical and molecular database of patient results, examining 2,167 patients with pancreatic cysts that underwent multiple PancraGEN tests over time. The results support the high negative predictive value of PancraGEN, showing that the majority of cases (92%) initially found to have low risk PancraGEN results remained low risk at follow-up. The small portion of patients that did progress only progressed to moderate risk levels, where risk most often regressed to low risk over time.

In addition to the poster, Interpace will host its second annual Fellows program. The keynote speakers will be Dr. Tamas Gonda, Columbia University, and Dr. James Farrell, Yale University. Dr.s Gonda and Farrell are going to be discussing their peer-reviewed published work on the utility of DNA analysis in managing patients with pancreatic cysts, describing molecular results of patients who have undergone PancraGEN testing and how those results can be used to impact patient management decisions.

About Interpace

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to the fact that there is no assurance the acquisition of the BioPharma business of Cancer Genetics, Inc. will be successfully integrated with the Company, or that the potential benefits of the acquisition, including future revenues, will be successfully realized. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Story continues

Read more from the original source:
Interpace to Present at the American College of Gastroenterology Conference - Yahoo Finance

The life sciences or biological sciences comprise the branches of science that involve the scientific study of life and organisms such as microorganisms, plants, and animals including human beings.

Life science is one of the two major branches of natural science, the other being physical science, which is concerned with non-living matter.

By definition, biology is the natural science that studies life and living organisms, with the other life sciences being its sub-disciplines.

Some life sciences focus on a specific type of organism. For example, zoology is the study of animals, while botany is the study of plants. Other life sciences focus on aspects common to all or many life forms, such as anatomy and genetics. Some focus on the micro scale (e.g. molecular biology, biochemistry) other on larger scales (e.g. cytology, immunology, ethology, ecology). Another major, branch of life sciences involves understanding the mind neuroscience.

Life sciences discoveries are helpful in improving the quality and standard of life, and have applications in health, agriculture, medicine, and the pharmaceutical and food science industries.

Biology burst and eclectic field, composed of many branches and sub-disciplines. However, despite the complexity and the broad scope of the science, there are certain general and unifying concepts within it that govern all study and research, consolidating it into a single, coherent field. Here are some of biology's major branches:

Go here to see the original:
List of life sciences - Wikipedia

Some smokers have more of an urge to light up right after they wake up, and UW-Madison researchers have identified a reason: genetic variation in a substance that breaks down nicotine in the brain.

The finding, by scientists at UW-Madison and Washington University in St. Louis, adds to growing research on genetic links to how much people smoke, how hard it is for them to quit and how likely they are to develop lung cancer.

Most of the attention has focused on genetic variation in enzymes that metabolize nicotine in the liver. Some studies suggest that dozens of genes could influence how addicted people become to smoking.

The new understanding about FMO3, an enzyme that metabolizes nicotine in the brain, could someday allow researchers to tailor tobacco cessation treatments to individual patients or develop new drugs to target the enzyme.

The research clearly suggests that its not just one or two big players here, but that a lot of genes may contribute to these outcomes, said Tim Baker, director of research at UW-Madisons Center for Tobacco Research and Intervention.

Despite a steady decline in smoking in recent years, tobacco remains the leading cause of preventable death, according to the Centers for Disease Control and Prevention.

About 17.3 percent of Wisconsin adults smoked in 2015. Thats down from 20.9 percent in 2011. Still, nearly 800,000 adults and adolescents in the state continue to light up, resulting in about 7,700 deaths a year, according to the state Department of Health Services.

Nationally, 17.5 percent of adults smoked in 2015, and smoking causes 480,000 deaths a year, the CDC says. More than half of American smokers attempt to quit each year, but only 6 percent succeed.

The brain enzyme study, published earlier this year in The Pharmacogenomics Journal, involved 1,558 smokers, most of them in a study at UW-Madison of people who were trying to quit.

Smokers with genes that produce more FMO3, causing nicotine to be broken down more quickly in the brain, were more likely to say they smoke first thing in the morning a key indicator of nicotine dependence.

Even if they have a home smoking ban, they will go out into their porch or to the garage to have their cigarette right away, as soon as they get up, Baker said.

Smokers with certain genetic types of the liver enzymes respond better to nicotine replacement therapy, researchers have found. Its too early to tell if the same might be true for the brain enzyme.

The genetic information could eventually help more smokers quit, but Baker said they shouldnt wait.

Regardless of their genetic status, although some people are at greater risk than others, any kind of smoking is dangerous and they should do whatever they can to quit now, he said.

Go here to see the original:
UW-Madison study links nicotine addiction to genetic variation in ... - Madison.com

Intermountain Precision Genomics Core Laboratory announced today it is expanding RxMatch. The pharmacogenomics service the study of how genes affect a patients response to medication will be made available to all Intermountain Healthcare providers.

The growth of the effort is indicative of how precision medicine programs across the world are taking off like never before, fueled by the adoption of early diagnosis, an increasing number of adverse drug reaction cases, high prevalence of chronic diseaseand advancements in genetic science.

The global precision medicine market is expected to reach $141.7 billion by 2026, according to a recent report by BIS Research.

The Intermountain lab launched RxMatch as an antidepressant panel in September 2017, the RxMatch Comprehensive Panel introduced today expands the gene targets from 36 to 97.

The panel includes opioids, statins, immune-suppressants, antidepressants and many more. Intermountain will integrate the resulting genomic medicine into clinical care while it also manages the information obtained through genomic sequencing, according to Intermountain.

The objective of this project is to provide the most comprehensive and evidence-based information to the physician," David Loughmiller, laboratory manager for Intermountain Precision Genomics, said in a statement. The result, Loughmiller noted, is decreasing the amount of time and money spent to achieve the correct medication.

The results are used to guide proper dosage based on a patients specific DNA genotype, Tom Neuwerth, clinical technology consultant for Intermountain Precision Genomics Lab, added. Small genetic variations impact how a patient metabolizes and responds to drugs. Our test helps ordering providers prescribe the right medication, at the right dose, at the right time.

Patients supply DNA samples using cheek swabs collected by their physicians. Once samples are received, the lab makes comprehensive reports available within a week.

Intermountains announcement comes just three days ahead of the HIMSS Precision Medicine Summit, slated for May 18-19, 2018 in the nations capital.

Twitter: @Bernie_HITNEmail the writer: bernie.monegain@himssmedia.com

View original post here:
Intermountain lab expands precision medicine with ...

PharmacogenomicsChoosing the right medication at the right dose for each patient

April 16, 2018

Did you know ... that the sequence of your genome can determine how you respond to certain medications?

Understanding pharmacogenomics, or tailoring a person's medications based on their genome, would not be possible without sequencing the genomes of many people and comparing their responses to medicines.

Oneof the most important uses for DNA sequencing is not to just sequence one human genome - but rather to sequence many human genomes to understand how genomic differences relate to different traits. Some such traits reflect physical characteristics (like eye color), whereas others can be used to help in the clinical care of patients. Scientists in the field of pharmacogenomics study how specific variants in your genome sequence influence your response to medications.

In order for our bodies to use some medicines properly, the cells in our bodies must make a few chemical changes that convert them into an active form, just like we do when we eat food. Then, these active forms of the medicine must get to the right places in the body or inside cells to do the job that we want them to do. If we want to make sure this happens, it makes sense that we would target our bodies' pathways involved in changing the medicine's form or in getting medicines to the right places. For example, you probably know someone who takes an antidepressant. Many of these medicines get to the right places by interacting with a protein called ABCB1,which works like a traffic cop on the outside of your cells.

Given ABCB1's important role in controlling traffic, you might imagine that if someone has a genomic variant that changes the shape or function of their ABCB1 protein, they might have a different response than usual to any number of medicines. We now know that is the case for some antidepressants, as well as other medications like statins for cholesterol and certain chemotherapy medicines. As a result, there are at least 18 pharmacogenomic tests for variants in ABCB1 listed in the NIH's Genetic Test Registry, with suggestions that you be tested for these variants to help determine the correct dose for certain medications.

Video courtesy of Mayo Clinic

Healthcare professionals and researchers are constantly seeking both to optimize medical treatments and to avoid adverse (or negative) reactions to treatments, which are estimated to affect between 7 percentand 14 percentof hospitalized patients. This makes adverse reactions a large cause of added days spent in a hospital, and the fourth leading cause of death in the United States.

One scary example of such an adverse reaction is Stevens-Johnson syndrome (SJS), a severe allergic reaction also called "scalded skin syndrome." It can be caused by infections, but also by very common medications like ibuprofen, anti-seizure medicines, or antibiotics. Patients may go from taking two pain pills to ending up in the hospital burn unit fighting for their lives if SJS progresses to a worse condition called toxic epidermal necrolysis (TEN). TEN is diagnosed when patients have shed at least one-third of the skin off of their bodies. Needless to say, anything we can do to prevent this allergic reaction is vitally important.

In Taiwan, married scientists Wen-Hung Chung (a physician) and Shuen-Iu Hung (an immunologist) noticed that SJS/TEN was much more common in patients taking carbamazepine, used to treat epilepsy and seizures, or allopurinol, used to treat gout. They showed that this was due to genomic variants in the HLA-B gene. Not surprisingly, this gene helps control the immune response. As a result of their work, the country of Thailand has implemented genomic testing before these medications are prescribed. The results of this "pharmacogenomic test" are used to decide whether it is safe to give a specific patient certain medicines, like carbamazepine or allopurinol. Thailand's government even covers the cost of this testing, and the frequency of SJS/TEN has been drastically reduced. We have since learned that different ancestries are associated with different HLA-B genomic variants, so countries may need to take different approaches to monitor which medications are most likely to be linked to SJS/TEN.

Video courtesy of Mayo Clinic

Understanding pharmacogenomics would not be possible without sequencing the genomes of many people and comparing them, and then comparing their response to medicines. But we have also learned that a person's genome sequence is not everything when it comes to medication responses. The human body is a very complicated machine, and the instructions written in our DNA are just part of the process.

There are some cases, as with the breast cancer treatment tamoxifen, where a small study showed that there might be a relationship between someone's response to the medicine and a variant in the CYP2D6 gene. However, this finding did not appear to be true in a larger study that involved many more people. That's why at this time, the U.S. Food and Drug Administration (FDA) labeling for tamoxifen does not recommend CYP2D6 pharmacogenomic testing, but the issue is still being reviewed as more research is conducted.

Another gene in the same CYP family, called CYP2C19, has variations which affect how your body can use clopidogrel (more commonly known as Plavix). This medication is a "blood thinner" which helps prevent blood clots, and thus reduces your risk of strokes or some heart attacks. If your CYP2C19 protein is not working properly due to a mutation in the gene, then you will not be able to process clopidogrel, and you need either a different dose or a different medication. As it turns out, these variants in CYP2C19 are also more common in those with Asian ancestry. Although testing for variants in this gene is also not routinely recommended, you may wish to speak with your healthcare provider about the test if you are given a prescription for clopidogrel, particularly if you have East Asian family members.

As the field of pharmacogenomics develops, more and more clinical trials will test for interactions between our genomes and the medicines we take. If you are interested in participating in such trials, you can search the ClinicalTrials.gov registry and look for ongoing studies with your condition. If you are curious whether any of your medications are known to be associated with pharmacogenomic information, check out the Pharmacogenomics Knowledge Database and speak with your medical care team. And, if you'd like to be part of a national effort along with one million other people that will involve pharmacogenomics research, look into the National Institute of Health's All of Us program.

Posted: April 16, 2018

Go here to see the original:
April 16: Pharmacogenomics - National Human Genome ...

DUBLIN, March 13, 2020 /PRNewswire/ -- The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The worldwide analgesic markets were analyzed for the year 2018 and projected to 2028. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 76 tables, 24 figures, and 600 selected references to the literature.

Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 173 of these are profiled in the report along with 156 collaborations. These are a mix of pharmaceutical companies and biotechnology companies.

The report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging.

Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan.

Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such astransdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain.

The wide variety of drugs in development includes opioid receptor ligands, bradykinin antagonists, mPGES-1 inhibitors, glutamate receptor antagonists, substance P and neurokinin receptor antagonists, norepinephrine transporter inhibitors,P2X2 neuron receptor antagonists and nitric oxide-based analgesics. A number of cannabinoids are also in development for pain. Fish-derived tetrodotoxin was initially focused on indication of opiate addiction withdrawal but is found to have an analgesic action as well. Cone shells contain therapeutically useful peptides including the conotoxins, and one such peptide, ziconotide, has been approved. Various cell and gene therapies are also being developed for the management of pain.

Advances in molecular and biological techniques are markedly advancing our undestanding of pain. Understanding the pathophysiology of pain is an important factor in discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain.

Key Topics Covered

Executive Summary1. Basic Aspects of Pain2. Assessment of Pain & Analgesics3. Pharmacotherapy of Pain4. Management of Pain5. Drug Delivery for Pain6. Drug Development for Pain7. Safety, Regulatory and Legal Issues of Pain Management8. Pain Markets9. Future of Pain Therapeutics10. Companies Involved in Pain Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/x962ke

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/pain-therapeutics-market-forecasts-to-2028---advances-in-pharmacogenomics--pharmacogenetics-enabling-the-development-of-personalized-management-301022861.html

SOURCE Research and Markets

See the original post here:
Pain Therapeutics Market Forecasts to 2028 - Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Management - P&T...

Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of Massachusetts for all product lines.

Interpace continues to expand in-network agreements and medical coverage for its services with leading National and Regional health plans, while maintaining Medicare coverage through Novitas Solutions.

According to Jack Stover, CEO of Interpace, This contract with Blue Cross Blue Shield of Massachusetts continues our trend of establishing improved reimbursement through participation as an in-network provider. Im pleased to announce that this is the first contract secured by our new VP of Managed Care and Payer Relations, Jeff Salzman.

AboutThyroid Nodules, ThyGeNEXT and ThyraMIR Testing

According to theAmerican Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

AboutInterpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

The Interpace Diagnostics division provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

The Interpace Pharma Solutions division provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Pharma Solutions Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's filings with the SEC, including without limitation, the Annual Report on Form 10-K and the companys Quarterly Reports filed with the SEC. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace DiagnosticsInvestor Relations:Joe Green(646) 653-7030jgreen@edisongroup.comEdison Group

See the rest here:
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts - GlobeNewswire

Meticulous Research leading global market research company is researching on precision medicine software market titled Precision Medicine Software Market by Delivery Mode (On-Premise, Cloud-Based), Application (Oncology, Pharmacogenomics, rare diseases), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Geography-Global Forecast to 2025.

Nowadays, rising advances in big data technology applications for accurate disease detection is creating a positive impact on the precision medicine software market over the forecast period. Moreover, the introduction of various software with an improved clinical workflow will likely increase the ability to store a large amount of genetic data to ensure rapid patient recovery. The factors such as growing acceptance of big data analysis and sequencing of gene therapy are expected to drive the growth of the precision software market during the forecast period.

Download Free Sample Copy Of The Report:: https://www.meticulousresearch.com/download-sample-report/cp_id=5011

Key questions answered in the report-

What are the major drivers, restraints, challenges, and opportunities in the precision medicine software market?

Who are the major players in various countries and what share of the market do they hold?

What are the geographical trends and high growth regions/ countries?

Who are the top competitors in this market and what strategies do they employ to gain shares?

What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?

What strategies should new companies looking to enter in this market use to compete effectively?

Who are the major players in the global precision medicine software market and what share of the market do they hold?

What are the local emerging players in the global precision medicine software market and how do they compete with the global players?

Have Any Query? Ask Our Expert https://www.meticulousresearch.com/speak-to-analyst/cp_id=5011

(In case of any queries or customization requirements please connect with our Experts by Clicking Here who will ensure that your requirements are met.)

On-Premise Delivery Mode Dominated the Precision Medicine Software Market in 2018

On the basis of delivery mode, the precision medicine software market is segmented into on-premise and cloud-based delivery model. On-premises commanded the largest share of precision medicine software market in 2018. The large market share of this segment is primarily attributed to the wide range of advantages regarding the use of on-premise delivery model. However, cloud-based delivery mode segment is expected to grow at the highest rate during the forecast period due to its rising adoption in healthcare organizations for sharing and integrating information from different locations.

Health Providers to Register the Highest Growth, by End User

On the basis of end user, the precision farming software market is segmented into healthcare providers, research centers & government institutes, pharmaceutical & biotechnology companies, and others. Health provider commanded the largest share of the precision software market in 2018 with the growing availability of precision medicine software and a rising emphasis on providing personalized medicine in hospitals.

You Can Directly Buy This Report From Here:: https://www.meticulousresearch.com/buy_now.php?pformat=310&vformat=921

(Get key industry insights spread across 280 pages with 256 market data tables & 61 figures & charts from the report)

North America Dominates the Market, While Asia Pacific Leads the Growth

North America commanded the largest share of the precision medicine software market in 2018, followed by Europe and Asia Pacific. The major share of this region is mainly attributed to the increase in the geriatric population suffering from chronic diseases such as cancer. In addition, rising government investment and favorable initiatives for the implementation of precision medicine software further support the growth of the North American precision medicine software market. However, Asia-Pacific region is projected to grow at a significant pace in the next few years, mainly due to the growing burden of genetic diseases throughout the region.

Key Players in the Precision Medicine Software Market

The key players operating in the globalprecision medicine software marketareSyapse, Inc. (U.S.), Fabric Genomics, Inc (U.S.), SOPHiA GENETICS SA (France), Human Longevity, Inc. (U.S.), Sunquest Information Systems, Inc. (U.S.), Lifeomic Health, LLC (U.S.), 2bPrecise LLC (U.S.), Foundation Medicine Inc. (U.S.), PierianDx Inc. (U.S.), Gene42 Inc. (Canada), N-of-One Inc. (A Subsidiary of Qiagen N.V.) (U.S.), and Translational Software Inc. (U.S.).

Download Free Sample Copy Of The Report:: https://www.meticulousresearch.com/download-sample-report/cp_id=5011

Related Reports::

1Healthcare Barcode Technology Market Size by Product (Barcode Printers, Barcode Verifiers, and Barcode Scanners) by application (Clinical and Non-Clinical) Global Forecasts to 2022

2 Artificial Intelligence In Healthcare Market By Product (Hardware, Software, Services), Technology (Machine Learning, Context-Aware Computing, NLP), Application (Drug Discovery, Precision Medicine), End User, And Geography Global Forecast To 2025

3 Clinical Trial Materials and Supplies Market by Service (Logistics, Manufacturing), Clinical Trial Type (Therapeutic, Diagnostics), Phase (Phase 2, Phase 3), Medical Specialty (Oncology, Diabetes), and End User (Pharmaceutical, CRO)- Global Forecast to 2025

About Meticulous Research

The name of our company defines our services, strengths, and values. Since its inception, we have only thrived to research, analyze and present the critical market data with great attention to details. Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

Contact Us:

Meticulous ResearchEmail-sales@meticulousresearch.comContact Sales- +1-646-781-8004Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Originally posted here:
Precision Medicine Software Market to Register the Highest Growth Rate by Applications, and Future F - PharmiWeb.com

Coherent Market Insights proclaims the obtainability of a new statistical data to its repository titled as, Pharmacogenomics market 2020 2027. It covers the wide-ranging aspects of the businesses such as pillars, features, sales strategies, planning models to get better insights for the businesses. Furthermore, it throws light on recent developments and technological platforms, several tools, and methodologies that help to boost the performance of industries.

This Pharmacogenomics Market report profiles major topmost manufactures operating Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc. in terms of analyse various attributes such as Production, Consumption, Revenue, Gross Margin, Cost, Gross, Market Share, CAGR, and Market Influencing Factors of the Pharmacogenomics industry in USA, EU, China, India, Japan and other regions.

Download PDF with Recent all Updates & Trending Key Players with TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1053

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Pharmacogenomics Market Taxonomy

The Pharmacogenomics Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts and industry participants across the value chain. The research report market provides an in depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Geographically, this report is segmented into several key regions,with sales, revenue, market share and growth Rate of Pharmacogenomics in these regions, from 2019 to 2027, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Different sales strategies have been elaborated to get a clear idea for getting global clients rapidly. It helps various industry experts, policymakers, business owners as well as various c level people to make informed decisions in the businesses. It includes the massive data relating to the technological advancements, trending products or services observed in the market. The major key pillars of businesses such as global Pharmacogenomics market are explained in a concise manner and effectively for fueling the progress of the market.

Our Study Report Offers:

Market share analysis for the regional and country level segments.

Pharmacogenomics Market share analysis of the best business players.

Strategic proposal for the new entrants.

Market forecasts for next five years of all the mentioned segments, sub segments and conjointly the regional markets.

Market Opportunities, Trends, Constraints, Threats, Challenges, Drivers, Investment and suggestions.

Strategic steerage in key business segments supported the market estimations.

Competitive landscaping mapping the key common trends.

Company identification with careful methods, financials, and up so far developments.

provide chain trends mapping the foremost recent technological advancements.

The reports conclusion reveals the overall scope of the Global Pharmacogenomics Market in terms of feasibility of investments in the various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the market in the near future.

Queries regarding the report can be addressed to Coherent Market Insights analysts @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1053

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

See the rest here:
Pharmacogenomics Market In-depth Study on Analysis and Forecast 2020-2027 - Redhill Local Councillors

The Pharmacogenomics Market report emphasizes Key players strategic movements including public relations activities, brand expansions, and product releases. It furnishes about Pharmacogenomics industry supply chain, processing techniques, market entry strategies, investment plans, retailers, and the economic impact on the stock exchange. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client of the Pharmacogenomics Market. This report also include some market-related illustrations and presentations, including pie charts, which represent the percentage division of strategies adopted by the major players in the global market.

Competitive Landscape

Global Pharmacogenomics market is highly cleft and the key players have used numerous plans such as new product launches, acquisitions, mergers, collaborations, innovation in products, expansions, agreements, joint ventures, and others to increase their footmarks in this market.

For Better Understanding, Download Free Sample Copy Of Pharmacogenomics Market Report In Just One Single Step At:https://marketresearch.biz/report/pharmacogenomics-market/request-sample

Key companies profiled in Pharmacogenomics Market report are: Empire Genomics LLC, Thermo Fisher Scientific Inc, Hoffmann-La Roche AG, Assurex Health Inc, Illumina Inc, Myriad Genetics Inc, OPKO Health Inc (GeneDx), Dynamic DNA Laboratories, OneOme LLC and Abbott Laboratories

The report further provides the following information:

Comprehensive analysis of the factors, drivers, and restraints impacting the share, size, and overall growth of the market.

Careful segregation of the market into different segments and in-depth research into the individual segments.

An exhaustive study of the regional and competitive aspects influencing the development of the market.

The report offered Segmentation:

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthersSegmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthersSegmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

All of the Technology, Application, End User, And Region segments of the global Pharmacogenomics market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

Regional Analysis:

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Pharmacogenomics market.

2. To provide insights about factors affecting the market growth. To analyse the Pharmacogenomics market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyse competitive developments such as strategic alliances, joint ventures, mergers and acquisitions, new product developments, and research and developments in the global Pharmacogenomics market.

Customize Report AndInquiry For The Pharmacogenomics Market Report:https://marketresearch.biz/report/pharmacogenomics-market/#inquiry

Table of Content

1 Pharmacogenomics Market Overview

2 Global Pharmacogenomics Market Competition by Manufacturers

3 Global Pharmacogenomics Production Market Share by Regions

4 Global Pharmacogenomics Consumption by Regions

5 Global Pharmacogenomics Production, Revenue, Price Trend by Type

6 Global Pharmacogenomics Market Analysis by Applications

7 Company Profiles and Key Figures in Pharmacogenomics Business

8 Pharmacogenomics Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Global Pharmacogenomics Market Forecast

12 Research Findings and Conclusion

13 Methodology and Data Source

Who we are and what we do:

MarketResearch.biz (https://marketresearch.biz) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined, we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Find More Reports:

Interior Doors Market

View original post here:
Pharmacogenomics Market Report Offers A One-Stop Solution To All The Key Players | Dynamic DNA Laboratories, Empire Genomics LLC and Abbott...

We don't always get what we want. But that shouldn't stop us from wishing, right?

So we reached out to executives around healthcare to get their wish lists for the industry as we enter the next decade.

From taking on regulatory requirements to better harnessing telehealth, here's what they had to say.

Top health industry issues of 2020: Will digital start to show an ROI?

Each year, PwC's Health Research Institute (HRI) names the top issues for the health industry in the coming year. What made the list for 2020? Join HRI for a discussion of the most important trends for providers, insurers, pharma/life sciences and employers.

"With the continued focus on bringing down the cost of healthcare, payers and employers will increasingly join providers in urging people to access the right level of care in lower-acuity settings rather than going to the ED. This will continue the acceleration of consumer-direct access to care options such as in-home, digital and local retail locations."

We need to move away from politics as usual. It is my hope that we can come together to drive solutions that make our healthcare system more efficient and prioritize the patients needs above all. Lets remove regulatory requirements to empower providers to focus on the delivery of care instead of needless administration. As the worlds largest economy, we simply have to prioritize the health of all of our people."

Lloyd Dean, co-CEO of CommonSpirit Health

"Top of mind is increased focus on using telehealth to meet the needs of the most vulnerable: the oldest and youngest on the spectrum as well as the sickest and poorest.

Weve gotten good at targeting telehealth to younger, tech-savvier, affluent patients in their 20s, 30s and 40s. But we need to pay closer attention to where telehealth is needed most and can have a profound impact. Telehealth holds strong potential to help patients with serious and chronic conditions, such as cancer, diabetes and COPD, who typically require more frequent engagement to stay out of the hospital.

Roy Schoenberg, M.D., president and CEO, American Well

"Id like to see the industry adopt more care management policies that encourage patients to manage their safety, healthcare and data via tested digital applications. In 2020 there should be greater adoption and more rapid application of pharmacogenomics into workflow process for patients and prescribers. The fact that the FDA is holding back pharmacogenomics is short-sighted. Pharmacogenomics ought to be fully embraced along with pharmacists who use technology-enabled tools to clinically apply data real-time and store data for future use as well.

Care practices should also be expanded so that pharmacists can be first-line primary care providers through physician collaboration or on their own. As healthcare organizations and payers transform how healthcare is defined and paid for, it will essential for pharmacists to step out from behind the counter to play a larger role in advising care, managing treatment and other clinical care services such as approving refills based on certain parameters."

Orsula V. Knowlton, president, chief marketing/new business development officer,Tabula Rasa HealthCare

"With impeachment looming and the 2020 presidential election set to take center stage, it will be hard for antimicrobial resistance to break through the noise in the media. I hope to read that Washington lawmakers put partisan politics aside and prioritize policies that will save millions of lives. When it comes to legislation to fight superbugs, we need a package of incentivesincluding Medicare reimbursement reforms, pull incentives to reward FDA approval of novel antimicrobials and push incentives to support research and development programs.

The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act is a good first step. The DISARM Act would increase Medicare funding to hospitals that appropriately use innovative antibiotics. The Centers for Medicare & Medicaid Services recently finalized a rule that would allow hospitals to receive additional Medicare reimbursement for prescribing newer antibiotics to treat drug-resistant infections. I hope to see more policy solutions that build on the DISARM Act to incentivize drug companies to fund antibiotic research."

GregFrank, director of Working to Fight AMR

See the article here:
We asked health execs for their 2020 wish lists. Here's what they said - FierceHealthcare

DUBLIN, Jan. 31, 2020 /PRNewswire/ -- The "Global Drug Discovery Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.

There are significant market opportunities for growth in the drug discovery market. Many healthcare industries are making investments in improving Big Data analytics to reduce inefficiency and provide services at affordable costs. The rising demand for specialty medicine is also expected to boost the small molecule drug discovery and hence, create growth opportunities for the drug discovery market.According to this research, the global drug discovery market is estimated to grow exponentially during the forecasting period 2019-2027 in terms of revenue at a CAGR of 8.28%.

An increase in the aged population, rise in healthcare expenses, growth in lifestyle-oriented diseases, and technological advancements are the major factors that are driving the overall growth of the drug discovery market. Rigid government regulations and poor reimbursement policies are some of the challenges that are restraining market growth.

Regional Outlook

The drug discovery market in Asia-Pacific is projecting an upward trend, and it is fastest-growing among the regions. The increasing GDP of various countries in the region have influenced the market growth. In countries like China and India, public as well as private sectors are investing huge amounts to support drug discovery.

Japan is known for its technological advancements in several industries. For instance, Japanese corporations have invented a revolutionary system named Peptide Discovery Platform System (PPDS), which helps to manually create millions of various kinds of peptides and extract it for the new drug. This invention has given a new approach to drug discovery.

Agilient Technologies, Inc. is a public research, development and manufacturing company that provides bio-analytical solutions and services to different sectors like diagnostics and genomics, chemical analysis, life sciences, electronics industries, and communications across the world. The company conducts its research to produce innovative and advanced products & services. The company was awarded as one of America's Best Employer For Diversity 2019 by Forbes.

Key Topics Covered:

1. Global Drug Discovery Market - Summary

2. Industry Outlook2.1. Market Definition2.2. Porter's Five Forces Model2.3. Pestle Outlook2.4. Regulatory Framework2.5. Value Chain Outlook2.6. Market Attractiveness Index2.7. Key Insight2.8. Market Drivers2.8.1. Growing Aged Population2.8.2. Technological Advancements2.8.3. Rise in the Healthcare Expenditure2.8.4. Surge in Lifestyle Oriented Diseases2.9. Market Restraints2.9.1. Delay in Product Launches2.9.2. Restricting Growth Rate of A Drug Due to Generic Drugs2.10. Market Opportunities2.10.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities2.10.2. Rising Demand for Specialty Medicines2.11. Market Challenges2.11.1. Poor Reimbursements Policies in Emerging Nations2.11.2. Stringent Government Regulations

3. Drug Discovery Market Outlook - By Drug Type3.1. Small Molecule Drug3.2. Biologic Drug

4. Drug Discovery Market Outlook - By Technology4.1. High Throughput Screening4.2. Biochips4.3. Bioinformatics4.4. Pharmacogenomics and Pharmacogenetics4.5. Combinatorial Chemistry4.6. Nanotechnology4.7. Spectroscopy4.8. Metabolomics4.9. Other Technologies

5. Drug Discovery Market Outlook - By Service5.1. Drug Metabolism and Pharmacokinetics (DMPK) Services5.2. Chemical Services5.3. Biological Services5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook - By End-User6.1. Research Institutes6.2. Pharmaceutical Companies6.3. Contract Research Organizations (CROs)6.4. Other End-Users

7. Drug Discovery Market - Regional Outlook

8. Company Profiles

9. Research Methodology & Scope

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/slactg

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Global Drug Discovery Market 2019-2027: Market is Poised to Grow at a CAGR of 8.28% from 2019-2027 - PRNewswire

Clinical laboratories with strong digital and information technology capabilities may find opportunities in this growing field of healthcare

Digital therapeutics (DTx), a growing trend in life sciences technology, is emerging as a popular form of connected healthcare physicians can use to transform patient behavior and improve clinical outcomes. This development may create opportunities for IT-savvy clinical laboratories.

The software applications (apps) and hardware monitoring devices involved in digital therapeutics enable physicians and patients to target and alter specific behaviors that affect certain medical conditions, such as substance abuse or depression. Combined with or without drugs, digital therapeutics are achieving positive results, according to the United Kingdoms PwC (PricewaterhouseCoopers) Health Research Institute (PwC HRI).

Clinical laboratory leaders engaged in precision medicine and pharmacogenomic initiatives will be intrigued by potential opportunities to support digital therapeutics. The FDAs Digital Software Precertification Program has already begun awarding approvals for digital therapeutics that address diabetes and central nervous system disorders, in addition to substance abuse and birth control.

And more FDA approvals for digital therapeutics are expectedin 2020, PwC HRI predicted.

Pharmaceutical and Tech Companies Collaborate on DigitalTherapeutics

A PwC report, titled, Top Health Industry Issues of 2019: The New Health Economy Comes of Age, describes digital therapeutics is an emerging health discipline that uses technology to augment or even replace active drugs in disease treatment.

The report goes on to state that digital therapeutics isreshaping the landscape for new medicines, product reimbursement and regulatoryoversight [and that] new data sharing processes and payment models will beestablished to integrate these products into the broader treatment arsenal andregulatory structure for drug and device approvals.

Connected health services, the report continues, enabled by devices that transmit data or connect to the Internet, give additional visibility into care delivery and new ways to improve patient outcomes.

Digital therapeutics combine apps and monitoring devices forthe management and treatment of medical conditions. While similar to customerwellness apps, digital therapeutics focus on specific clinical outcomes.

The non-profit Digital Therapeutics Alliance says that, unlike common wellness apps, digital therapeutics possess the unique ability to incorporate additional functionalities into a comprehensive portfolio of synchronous products and services. This includes potential integration with mobile health platforms; the provision of complementary diagnostic or adherence interventions; the ability to pair with devices, sensors, or wearables; the delivery of interventions remotely; and integration into electronic prescribing, dispensing, and medical record platforms.

Digital therapeutics are the next frontier, Sai Jasti, Chief Data and Analytics Officer, GlaxoSmithKline (NYSE:GSK), told PwC HRI. I think we will see a lot more collaboration between pharmaceutical and technology companies to drive this forward, ultimately to the benefit of patients.

Digital Therapeutics That Already Have FDA Approval

Digital therapeutics and their connected devices are subjectto the approval process of the federal Food and Drug Administration (FDA), andsome have already received that coveted clearance:

Digital technologies and data science have incredible potential to unlock the next chapter of medical innovation and to help individuals finally take control of their own health in a meaningful way, said Richard Francis, Division Head and CEO, Sandoz, in a press release. New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their therapies and thus improve patient outcomes.

Both reSET and reSET-O are software mobile apps that use cognitive behavioral therapy (CBT) to help individuals struggling with addictions.

Nearly 50,000 drug overdose deaths involving opioids, including prescription pain medications and heroin, took place in the U.S. in 2017, said Corey McCann, MD, PhD, President and CEO of Pear Therapeutics, in the press release following receiving FDA approval. There is an urgent need for new and innovative therapeutics to address this public health epidemic. This groundbreaking decision by the FDA ushers in a new standard for treating patients with Opioid Use Disorder and it signals a new path for therapeutic software to be used in conjunction with pharmacotherapy to improve efficacy.

We know that women are more likely to use contraceptive methods when they have a variety of methods available to them, and the reality is that not every method is going to work for every woman, Rebecca Simmons, PhD, Research Assistant Professor, Department of Obstetrics and Gynecology, University of Utah, told Health. This is really exciting, in the sense that the more methods we have, the more likely it is that people can find something that works for themand then can avoid unwanted pregnancy.

The role that technology plays in allowing patients to capture meaningful data about whats happening with their heartat the moment when its happening, like the functionality of an on-demand ECGcould be significant in new clinical care models and shared decision-making between people and their healthcare providers, said Nancy Brown, CEO of the American Heart Association, in a press release.

Patients, Providers, and Big Pharma All Like DigitalTherapeutics

There is some evidence that patients and healthcareproviders are intrigued and willing to try digital therapeutics. In a PwC HRI survey,more than 50% of respondents said they would be somewhat or very likely to tryan FDA-approved app or online tool for treatment of a medical condition.

Pharmaceutical companies also are interested in digital therapeutics. A 2018 PwC HRI survey found that 80% of pharmaceutical executives had plans to invest in digital therapeutics in the near future.

A 2019 PwC article, titled, Digital Health Products Need Evidence and Buy-In to Succeed, states that drug companies see the following opportunities for DTx to improve the patient experience:

With precision medicine and pharmacogenetics, clinical laboratoriescould play an essential role in supporting digital therapeutics in the future. Butto truly be competitive in this space and take advantage of the opportunity, medicallaboratories will need to increase their information technology and digitalcapabilities.

JP Schlingman

Related Information:

Digital Therapeutics and Connected Care Reshape the Life Sciences Industry

The Emerging World of Digital Therapeutics

Top Health Industry Issues of 2019: The New Health Economy Comes of Age

Digital Therapeutics: Combining Technology and Evidence-based Medicine to Transform Personalized Patient Care

Everything You Need to Know About the Controversial New Birth Control App

Digital Health Software Precertification (Pre-Cert) Program

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for Reset-O to Treat Opioid Use Disorder

Everything You Need to Know About the Controversial New Birth Control App

More than Half of Patients Willing to Use Digital Therapeutic, Study Says

ECG App and Irregular Heart Rhythm Notification Available Today on Apple Watch

Digital Health Products Need Evidence and Buy-in to Succeed

Life Sciences May See Accelerated Digital Health Pathway as Soon as 2020

See the original post here:
FDA Approves Digital Therapeutics Technologies to Treat Patient Behavioral Conditions That Interfere with Positive Healthcare Outcomes - DARKDaily.com...

Clinical Implementation of Pharmacogenomics

Pharmacogenomics has the potential to influence clinically relevant outcomes in drug dosing, efficacy, and toxicity that can result in subsequent recommendations for testing. For many routinely used drugs, pharmacogenomics has provided inconclusive evidence for such testing. A probable reason could be the involvement of both genetic and nongenetic factors and their extent of contribution that determines the clinical relevance of some drugs. Therefore, identification of genetic markers associated with drug responses does not always link to clinically useful predictors of adverse outcomes, and most of the time require independent replication of genotypephenotype association before pursuing clinical implementation.

Lack of readily available resources, feasibility, utility, level of evidence, provider knowledge, cost effectiveness, and ethical, legal, and social issues further adds to the limitations and challenges to implementing pharmacogenomic testing in clinical practice. In order for a genetic marker to be implicated in clinical practice, an association of a genetic marker to a particular trait requires screening of tissues from several individuals, and corresponding functional studies are needed to establish probable association with the trait/phenotype. However, to overcome these challenges there are some pharmacogenomic tests for drugs currently used in clinical practice that have applied value in predicting ADRs and/or drug efficacy. Table 7.2 lists some of these clinically valuable pharmacogenomics tests. These tests are based on distinct genetic variants that have well-validated reproducible and significant impact on the drug therapy. These tests have a strong causal association between genetic polymorphisms and drug responses: a strong indication for clinical utility and high prognostic value. The tests are available both commercially and in academic settings, with many of these tests having clinical guidelines for dose adjustment and alternative medications (Wei et al., 2012). In addition, various international pharmacogenomic consortia have been developed recently to supervise drug response studies.

Table 7.2. Examples of Clinically Valuable Application of Pharmacogenomics Tests in Predicting Drug Response (Efficacy and Toxicity)

A list of current pharmacogenomic guidelines from these consortiums along with a well-annotated pharmacogenomic database has been consolidated into one curated database known as Pharmacogenomics Knowledge Base (PharmGKB) (Thorn et al., 2010). PharmGKB is available via an online portal where users can search on the website by gene, drug, metabolic pathway, and disease. To boost the clinical application of pharmacogenetics and address the barriers to implementation of pharmacogenetic tests into clinical practice CPIC was formed as a shared project between PharmGKB and the Pharmacogenomics Research Network (https://cpicpgx.org). CPIC provides freely available, peer-reviewed, updatable, and detailed gene/drug clinical practice guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. The guidelines can focus on genes (e.g., thiopurine methyltransferase and its implications for thiopurines) or around drugs (e.g., warfarin and CYP2C9 and VKORC1). Efforts like PharmGKB and CPIC can help to overcome the confusion created about various pharmacogenetic tests and can help clinical decision making. In addition, the FDA has created a table of Pharmacogenomic Biomarkers in Drug Labeling that lists FDA-approved drugs with pharmacogenomic information in their labeling (http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm). This biomarker table provides up to date information on genomic markers that have been referred in FDA package inserts for different drugs. Various biomarkers are included in this table, e.g., germ-line or somatic gene variants, functional deficiencies, expression changes, and chromosomal abnormalities as well as selected protein biomarkers that need to be tested before starting treatment in a selected subset of patients. Moreover, with continued integration of pharmacogenomics in clinical trials and drug development, novel important genes and variants that can predict drug efficacy and toxicity will be identified and can be implemented in clinical practice.

Read the original here:
Pharmacogenomics - an overview | ScienceDirect Topics